AC Immune SA Common Stock (ACIU)
Stock · NASDAQ · Health Care
$2.4as of 10/16/2026
Price chart
Active signals
ACIU Signal Track Record
How signals performed across all stocks →What ACIU's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -0.9% | 43% | September 23, 2026 |
| Bollinger Band Breakout | 24 | -10.5% | 29% | August 11, 2026 |
| Bollinger Band Breakdown | 20 | +3.5% | 50% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -3.0% | 43% | September 23, 2026 |
| Any 20-session window (baseline) | -1.2% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 90
- Website
- www.acimmune.com/
Fundamentals
- 1-day range
- $2.39$2.47
- Market cap
- $236.11M
- P/E (trailing)
- —
- P/E (forward)
- 3.99
- EPS (trailing)
- $-0.43
- Dividend yield
- —
- Beta
- 1.58
- Avg. volume
- 199.3K
Forecasts
4 analyst ratings
AC Immune SA Common Stock Competitors
Chosen by industry and closest market cap.
- ACIUAC Immune SA Common Stock$2.39▼ 2.45%Market cap $236.11MP/E —$2.1$4
- PYXSPyxis Oncology Inc. Common Stock$1.68▼ 6.67%Market cap $237.58MP/E —$1.03$5.55
- CAPRCapricor Therapeutics Inc. Common Stock$6.71▼ 7.70%Market cap $242.07MP/E —$2.96$40.37
- SLGLSol-Gel Technologies Ltd. Ordinary Shares$64.25▼ 6.48%Market cap $244.18MP/E —$28.81$97.97
- SIGASIGA Technologies Inc. Common Stock$3.17▼ 0.63%Market cap $223.78MP/E —$2.83$8.55
- WHWKWhitehawk Therapeutics Inc. Common Stock$2.89▼ 4.93%Market cap $252.78MP/E —$1.97$5.5
- ANTXAN2 Therapeutics Inc. Common Stock$3.38▼ 6.11%Market cap $218.98MP/E —$1$7.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ACIU AC Immune SA Common Stock | $236.11M | — | $2.39 | ▼ 2.45% | $2.1$4 |
| PYXS Pyxis Oncology Inc. Common Stock | $237.58M | — | $1.68 | ▼ 6.67% | $1.03$5.55 |
| CAPR Capricor Therapeutics Inc. Common Stock | $242.07M | — | $6.71 | ▼ 7.70% | $2.96$40.37 |
| SLGL Sol-Gel Technologies Ltd. Ordinary Shares | $244.18M | — | $64.25 | ▼ 6.48% | $28.81$97.97 |
| SIGA SIGA Technologies Inc. Common Stock | $223.78M | — | $3.17 | ▼ 0.63% | $2.83$8.55 |
| WHWK Whitehawk Therapeutics Inc. Common Stock | $252.78M | — | $2.89 | ▼ 4.93% | $1.97$5.5 |
| ANTX AN2 Therapeutics Inc. Common Stock | $218.98M | — | $3.38 | ▼ 6.11% | $1$7.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- INSM Stock Slides on CFO Exit, Reiterates '26 Sales ViewYahoo · 10/6/2026
- AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowYahoo · 10/6/2026
- PCRX Expands Exparel Commercial Reach in Europe Through Molteni DealYahoo · 10/6/2026
- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealYahoo · 10/5/2026
- Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA ValidationYahoo · 10/5/2026
- Novo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkYahoo · 10/5/2026
- UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%Yahoo · 10/1/2026
- Novo's Wegovy Pill Shows Weight Loss After Switching From InjectionsYahoo · 10/1/2026
Insider Activity
Insider Actions →- Roy Ervin Twyman · June 11, 2026 · Grant38.9K
- Roy Ervin Twyman · June 11, 2026 · Grant16.6K
- Monika Buetler · June 11, 2026 · Grant41.7K
- Monika Buetler · June 11, 2026 · Grant17.8K
- Carl Howard June · June 11, 2026 · Grant38.9K
- Carl Howard June · June 11, 2026 · Grant16.6K
- Renee Aguiar-Lucander · June 11, 2026 · Grant38.9K
- Renee Aguiar-Lucander · June 11, 2026 · Grant16.6K
- Martin Zuegel · June 11, 2026 · Grant77.8K
- Martin Zuegel · June 11, 2026 · Grant33.1K
- Andrea Pfeifer · May 15, 2026 · Sale10.0K @ $2.79
- Andrea Pfeifer · April 15, 2026 · Sale10.0K @ $3.14
- Andrea Pfeifer · April 15, 2026 · Buy10.0K @ $3.14
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AC Immune Parkinson’s Vaccine Study Meets Safety and Immunogenicity Goals
AC Immune’s Parkinson’s vaccine study reached its safety and immunogenicity targets, a key milestone for the company’s pipeline. The company also reported ongoing progress in its ACI-7104 program and other pipeline expansions. This development comes as the stock trades near its 52‑week low, with a support level at $2.76.
AC Immune Parkinson’s Vaccine Study Meets Safety and Immunogenicity Goals. AC Immune’s Parkinson’s vaccine study reached its safety and immunogenicity targets, a key milestone for the company’s pipeline. The company also reported ongoing progress in its ACI-7104 program and other pipeline expansions. This development comes as the stock trades near its 52‑week low, with a support level at $2.76.